Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Key Takeaways Tirzepatide is a dual GIP/GLP-1 receptor agonist
The bigger issue is more about their combined effects than a clash between them
The FDA warned against the use of compounded semaglutide more broadly, noting that these reformulated therapies pose a higher risk to patients than approved medicines because they do not undergo FDA premarket review for safety, effectiveness or quality. Patients should only be on compounded medication if their medical needs cannot be met by an available FDA-approved drug. Weight-loss therapies have been growing rapidly in recent months, with Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide) currently dominating the space and other competitors looking target the lucrative market
GLP-1, on the other hand, is a specific peptide hormone secreted primarily by intestinal L-cells after you eat
"Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis." Clinical Nutrition ESPEN
W.JohariY.BurtonP
